Impact of genetic polymorphisms in the clinical response of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor

被引：0
|
作者：
Simon, T. [1 ]
机构：
[1] Univ Paris 06, AP HP, Serv Pharmacol, F-75252 Paris 05, France
来源：
ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE | 2010年 / 59卷
关键词：
Pharmacogenetics; Antiplatelet; Thienopyridine; Prognosis; Cardiovascular disease; PERCUTANEOUS CORONARY INTERVENTION; OF-FUNCTION POLYMORPHISM; STENT THROMBOSIS; ANTIAGGREGATING ACTIVITY; CYP2C19; GENOTYPE; CLOPIDOGREL; OUTCOMES; PRASUGREL; THERAPY; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Dual antiplatelet therapy with clopidogrel combined to aspirin reduces ischemic events in a wide range of patients with cardiovascular disease. However, a large interindividual variability has been observed in the pharmacodynamics response of clopidogrel with lower platelet inhibition associated with increased risk for major adverse cardiovascular events. Multiple mechanisms have been proposed for the variable response to clopidogrel, among which the impact of pharmacogenetic seems to play an important role. This article reviews the role of genetic polymorphisms in the clinical impact of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：S90 / S94
页数：5
相关论文
共 50 条
  • [31] Clopidogrel and ticlopidine:: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis
    Savi, P
    Herbert, JM
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (02): : 174 - 183
  • [32] Pharmacogenetics of P2Y12 receptor inhibitors
    Thomas, Cameron D. D.
    Williams, Alexis K. K.
    Lee, Craig R. R.
    Cavallari, Larisa H. H.
    PHARMACOTHERAPY, 2023, 43 (02): : 158 - 175
  • [33] Responsiveness to P2Y12 receptor inhibitors
    Esposito, Giovanni
    CURRENT OPINION IN CARDIOLOGY, 2011, 26 : S31 - S37
  • [34] A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models
    Wang, Yi-Xin
    Vincelette, Jon
    da Cunha, Valdeci
    Martin-McNulty, Baby
    Mallari, Cornell
    Fitch, Richard M.
    Alexander, Serene
    Islam, Imadul
    Buckman, Brad O.
    Yuan, Shendong
    Post, Joseph M.
    Subramanyam, Babu
    Vergona, Ronald
    Sullivan, Mark E.
    Dole, William R.
    Morser, John
    Bryant, Judi
    THROMBOSIS AND HAEMOSTASIS, 2007, 97 (05) : 847 - 855
  • [35] Pleiotropic Effects of Platelet P2Y12 Receptor Inhibitors: Fact or Fiction?
    Moulias, Athanasios
    Xanthopoulou, Ioanna
    Alexopoulos, Dimitrios
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (28) : 4597 - 4604
  • [36] Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests
    Valgimigli, Marco
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2013, 14 : S8 - S15
  • [37] Response Variability to P2Y12 Receptor Inhibitors Expectations and Reality
    Siller-Matula, Jolanta M.
    Trenk, Dietmar
    Schroer, Karsten
    Gawaz, Meinrad
    Kristensen, Steen D.
    Storey, Robert F.
    Huber, Kurt
    JACC-CARDIOVASCULAR INTERVENTIONS, 2013, 6 (11) : 1111 - 1128
  • [38] Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y12 antagonists
    Boncler, Magdalena
    Wzorek, Joanna
    Wolska, Nina
    Polak, Dawid
    Watala, Cezary
    Rozalski, Marcin
    VASCULAR PHARMACOLOGY, 2019, 113 : 47 - 56
  • [39] P2Y12 inhibitors - Thienopyridines and direct oral inhibitors
    Collet, J. -P.
    Montalescot, G.
    HAMOSTASEOLOGIE, 2009, 29 (04): : 339 - +
  • [40] Genetic variation in ADP-receptor P2Y12 and the risk of arterial thrombosis
    Rudez, G
    Bruijne, ELEDE
    Bongers, TN
    Dippelw, DWJ
    Deckers, J
    Poldermans, D
    De Maat, MPM
    Leebeek, FWG
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 45 - 45
12345